Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($0.14) per share. The company’s stock shows a 52-week range of $0.62–$2.93 and a market cap of $356.19 million, with notable institutional ownership. Wall Street analysts currently hold an average “Sell” rating for NAUT with a target price of $2.50.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday
Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($0.14) per share. The company’s stock shows a 52-week range of $0.62–$2.93 and a market cap of $356.19 million, with notable institutional ownership. Wall Street analysts currently hold an average “Sell” rating for NAUT with a target price of $2.50.